Education
About Us
Working with TipRanks
Follow Us
RegeneRx Biopharmaceuticals (RGRX)
OTHER OTC:RGRX
RGRX Stock Chart & Stats
$0.16
$0.00(0.00%)
At close: 4:00 PM EST
$0.16
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.07 - $0.16
Previous CloseN/A
Volume20.00
Average Volume (3M)205.00
Market Cap
$449.00
Enterprise Value$1.16M
Total Cash (Recent Filing)$101.56K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta79.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,496,966
10 Day Avg. Volume25
30 Day Avg. Volume205
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)-578.70
Price to Sales (P/S)25975.55
P/FCF Ratio-2.12K
Enterprise Value/Market Cap2.57K
Enterprise Value/Revenue15.06
Enterprise Value/Gross Profit15.06
Enterprise Value/Ebitda-3.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RGRX FAQ
What was RegeneRx Biopharmaceuticals’s price range in the past 12 months?
RegeneRx Biopharmaceuticals lowest stock price was $0.07 and its highest was $0.16 in the past 12 months.
What is RegeneRx Biopharmaceuticals’s market cap?
RegeneRx Biopharmaceuticals’s market cap is $449.00.
When is RegeneRx Biopharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RegeneRx Biopharmaceuticals’s earnings last quarter?
Currently, no data Available
Is RegeneRx Biopharmaceuticals overvalued?
According to Wall Street analysts RegeneRx Biopharmaceuticals’s price is currently Overvalued.
Does RegeneRx Biopharmaceuticals pay dividends?
RegeneRx Biopharmaceuticals does not currently pay dividends.
What is RegeneRx Biopharmaceuticals’s EPS estimate?
RegeneRx Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RegeneRx Biopharmaceuticals have?
RegeneRx Biopharmaceuticals has 1,496,966 shares outstanding.
What happened to RegeneRx Biopharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RegeneRx Biopharmaceuticals?
Currently, no hedge funds are holding shares in RGRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.